Case Report: A unique case of Philadelphia chromosome-positive mixed-phenotype acute leukemia with active Epstein-Barr virus infection in a kidney transplantation recipient - Scorecard - MDSpire
Advertisement
Case Report: A unique case of Philadelphia chromosome-positive mixed-phenotype acute leukemia with active Epstein-Barr virus infection in a kidney transplantation recipient
Clinical Scorecard: Case Study: An Uncommon Instance of Mixed-Phenotype Acute Leukemia with Philadelphia Chromosome and Active Epstein-Barr Virus in a Kidney Transplant Patient
At a Glance
Category
Detail
Condition
Mixed-phenotype acute leukemia (MPAL)
Key Mechanisms
Philadelphia chromosome-positive (Ph+) MPAL with concurrent Epstein-Barr virus (EBV) infection
Target Population
Renal transplant recipients
Care Setting
Oncology and transplant medicine
Key Highlights
Ph+ MPAL is a rare and aggressive form of acute leukemia.
Co-occurrence of EBV infection in a kidney transplant patient is exceptionally rare.
Tailored therapy combining olverembatinib, dexamethasone, azacitidine, and lisaftoclax was used.
B-cell–depleting therapy with rituximab was implemented for EBV viremia.
The patient achieved hematologic remission and clearance of EBV viremia.
Guideline-Based Recommendations
Diagnosis
Diagnosis of MPAL requires identification of myeloid and lymphoid markers.
Management
Combination therapy with targeted agents and supportive care is recommended.
Monitoring & Follow-up
Regular monitoring of blood counts and EBV viral load is essential.
Risks
High risk of relapse and poor long-term survival associated with MPAL.
Patient & Prescribing Data
Combination therapy led to complete remission and undetectable BCR-ABL1 transcript. [Source needed]
